Inovio Pharma (INO), Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate
Go back to Inovio Pharma (INO), Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate| INOVIO PHARMACEUTICALS, Inc. (NASDAQ: INO) | Delayed: 1.15 +0.04 (3.60%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.11 | 52 Week High | $11.69 | |||
| Open | $1.09 | 52 Week Low | $4.50 | |||
| Day High | $1.16 | P/E | N/A | |||
| Day Low | $1.09 | EPS | $-0.28 | |||
| Volume | 587,314 | |||||
